Johnson and Johnson, Philippine Psychiatric Association Launch Online Learning Platform for Filipino Psychiatrists

Johnson and Johnson (Philippines), Inc. (JJPI), in collaboration with the Philippine Psychiatric Association (PPA) is launching a new online learning series for Filipino psychiatrists, entitled the Neuroscience Academy.

The online learning series will be available exclusively on the Johnson & Johnson Institute digital learning platform for PPA members.

In this webinar series, JJPI and PPA will be covering topics that focus on clinical management of schizophrenia; a serious mental health condition that can result in a combination of hallucinations, delusions, extremely disorganized speech, thinking and behavior, as well as negative symptoms that impair daily function. According to the Philippine Health Information System on Mental Health conditions (PHIS-MH), schizophrenia remains as the top brain disorder in the Philippines, affecting at least 42 percent of patients who seek psychological consult, based on a survey gathered from 2,562 patients in 14 public and private hospitals.

The Neuroscience Academy will center around the appropriate use of long acting treatment (LAT), an innovative treatment option in the management of schizophrenia, with world-renowned professors and clinical practitioners in the field of psychiatry as resource speakers. These include Christoph

Correll, William Tak-Lam Lo, Wolfgang Fleischhacker, Jun Soo Kwon, Mathhew Warden, and many more.

PPA President Dr. Amadeo Alinea, Jr. said, “Our collaboration with J&J in creating this on-demand webinar series is aimed to provide our psychiatrists with continuous learning opportunities even in these challenging times.”

Alinea added that the variety of speakers will provide a rich learning experience for their colleagues, as it will allow for them to keep up-to-date with the latest findings in their field.

JJPI Country Director for Hospital Channel Wigbert Dennis R. Funtanilla, affirmed that the launch of the joint project is aligned with the Company’s thrust to continually bring innovative treatment options for schizophrenia in the country.

Johnson & Johnson has been a long-standing ally and advocate of the Philippines’ mental healthcare industry; from the introduction of a once-a-month paliperidone palmitate injection in 2012, to the recent approval of the first once every three months paliperidone palmitate injection, the Company has continually pushed for innovation in schizophrenia management.

JJPI President and Managing Director Raghu Krishnan shared, “As we navigate the ways of the “new normal,” we, as a Company, stand firm in our commitment to providing our partner-doctors and patients with the essential knowledge and solutions they need, that they may continue to care for themselves and others in these trying times.”

He added, “With the launch of the Neuroscience Academy, we hope to build a better and more responsive mental healthcare landscape in the country.”